Poxel Announces its Participation at Upcoming Scientific Conference
03 October 2023 - 2:45AM
Business Wire
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a
clinical stage biopharmaceutical company developing innovative
treatments for chronic serious diseases with metabolic
pathophysiology, including non-alcoholic steatohepatitis (NASH) and
rare metabolic disorders, today announced that it will participate
at the upcoming 12th International Meeting on AMPK on
October 4th, 2023.
Sophie Bozec, Executive Vice President, R&D Pharmacology and
Scientific Communication at Poxel, will host a virtual presentation
on “Direct AMPK Activation: From Preclinical to Clinical.
Perspectives in Rare Metabolic Diseases”. The presentation will
review Poxel’s molecule PXL770, which is a first-in-class direct
adenosine monophosphate-activated protein kinase (AMPK) activator,
focused on rare diseases treatment, including adrenoleukodystrophy
(ALD) and autosomal dominant polycystic kidney disease (ADPKD).
About Poxel SA Poxel is a clinical stage
biopharmaceutical company developing innovative treatments
for chronic serious diseases with metabolic pathophysiology,
including non-alcoholic steatohepatitis (NASH) and rare
disorders. For the treatment of NASH, PXL065
(deuterium-stabilized R-pioglitazone) met its primary endpoint in a
streamlined Phase 2 trial (DESTINY-1). In rare diseases,
development of PXL770, a first-in-class direct adenosine
monophosphate-activated protein kinase (AMPK) activator, is focused
on the treatment of adrenoleukodystrophy (ALD) and autosomal
dominant polycystic kidney disease (ADPKD). TWYMEEG®
(Imeglimin), Poxel’s first-in-class product that targets
mitochondrial dysfunction, is marketed for the treatment of type 2
diabetes in Japan by Sumitomo Pharma and Poxel expects to receive
royalties and sales-based payments. Poxel has a strategic
partnership with Sumitomo Pharma for Imeglimin in Japan, China, and
eleven other Asian countries. Listed on Euronext Paris, Poxel is
headquartered in Lyon, France, and has subsidiaries in Boston, MA,
and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements. The Company does not endorse or is
not otherwise responsible for the content of external hyperlinks
referred to in this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231002692378/en/
Investor relations / Media
Aurélie Bozza Investor Relations & Communication Senior
Director aurelie.bozza@poxelpharma.com +33 6 99 81 08 36
NewCap Nicolas Fossiez, Aurélie Manavarere / Arthur Rouillé
poxel@newcap.eu +33 1 44 71 94 94
Poxel (EU:POXEL)
Historical Stock Chart
From Apr 2024 to May 2024
Poxel (EU:POXEL)
Historical Stock Chart
From May 2023 to May 2024